Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 1997

View Archived Issues

Novel fibrinogen antagonist from Merck & Co.

Merck & Co. continues to develop 5alpha-reductase inhibitors

Thomae prepares fibrinogen receptor antagonists

Chiral TNF inhibitors reported by Schering AG

Clinical pharmacokinetics of nicotine after oral, i.v. and rectal administration

SR-BI receptor implicated in HDL metabolism

Chimeric molecule shows promise as thrombolytic therapy

Clinical results reported for Novo Nordisk insulinotropic agent

Miglitol tested in specific population subgroups

Efficacy of pioglitazone demonstrated in NIDDM patients

Midodrine efficacy in diabetic patients with orthostatic hypotension

Vical's Leuvectin enters phase I/II for prostate cancer

NIH funds high-throughput screening in allergic inflammation and immunology by Cadus

FDA Oncologic Drugs Advisory Committee to review three NDAs in late June

Cortecs' H. pylori diagnostic approved in Japan

NitroMed issued U.S. patent covering NO delivery compounds

Corlopam and Lovenox scheduled for advisory committee review

Milkhaus initiates phase II trial for prostate cancer

Oncor completes PMA for breast cancer test

Antifibrotic collaboration announced by ArQule and FibroGen

Cel-Sci receives approval to begin Multikine trial in Canada

Successful phase III trials of Cytolex trigger milestone payment for Magainin

ABS forms alliance with Russian Academy of Sciences

Long-term Enbrel safe and effective in RA

Update on Alpha-Beta's acquisition and Betafectin trial results timeline

Nevirapine for prophylaxis of HIV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...